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Third-generation cephalosporin resistance (3GC-R) in Escherichia coli is a rising 
problem in human and farmed animal populations. We conducted whole genome 
sequencing analysis of 138 representative 3GC-R isolates previously collected from 
dairy farms in South West England and confirmed by PCR to carry acquired 3GC-R 
genes. This analysis identified blaCTX-M (131 isolates: encoding CTX-M-1, -14, -15, -32 
and the novel variant, CTX-M-214), blaCMY-2 (6 isolates) and blaDHA-1 (one isolate). A 
highly conserved plasmid was identified in 73 isolates, representing 27 E. coli 
sequence types. This novel ~220 kb IncHI2 plasmid carrying blaCTX-M-32 was 
sequenced to closure and designated pMOO-32. It was found experimentally to be 
stable in cattle and human transconjugant E. coli even in the absence of selective 
pressure and was found by multiplex PCR to be present on 26 study farms 
representing a remarkable range of transmission over 1500 square kilometres. 
However, the plasmid was not found amongst human urinary E. coli we have recently 
characterised from people living in the same geographical location, collected in parallel 
with farm sampling. There were close relatives of two blaCTX-M plasmids circulating 
amongst eight human and two cattle isolates, and a closely related blaCMY-2 plasmid 
found in one cattle and one human isolate. However, phylogenetic evidence of recent 
sharing of 3GC-R strains between farms and humans in the same region was not 
found.  
Importance 
Third-generation cephalosporins (3GCs) are critically important antibacterials and 
3GC-resistance (3GC-R) threatens human health, particularly in the context of 
opportunistic pathogens such as Escherichia coli. There is some evidence for zoonotic 




possible transmission (e.g. via interaction of people with the local near-farm 
environment). We characterised acquired 3GC-R E. coli found on dairy farms in a 
geographically restricted region of the United Kingdom and compared these with E. 
coli from people living in the same region, collected in parallel. Whilst there is strong 
evidence for recent farm-to-farm transmission of 3GC-R strains and plasmids – 
including one epidemic plasmid that has a remarkable capacity to transmit – there was 
no evidence that 3GC-R found on study farms had a significant impact on circulating 





Third-generation cephalosporin-resistant (3GC-R) Escherichia coli have been 
increasingly reported in both animal and human populations and are considered 
pathogens of major concern for humans (1,2). 3GCs such as cefotaxime and 
ceftazidime have been listed by the World Health Organisation (WHO) as “highest-
priority critically important antimicrobials” (HP-CIAs) because of their importance for 
human health (3). Resistance to 3GCs in E. coli can be caused by several mechanisms 
but is primarily attributed to the acquisition of Extended Spectrum β-Lactamases 
(ESBLs) or plasmid-mediated AmpC β-lactamases (pAmpCs) (4). Plasmids encoding 
ESBLs and pAmpCs frequently harbour additional resistance genes and so can 
present a significant therapeutic challenge (5). In recent years, the promotion and 
implementation of the ‘One Health’ approach in antimicrobial resistance by the WHO 
has emphasised the importance of surveillance in both animal and human populations 
and has highlighted gaps in this knowledge (6). In humans it has been well established 
in numerous global studies that certain E. coli lineages (e.g. blaCTX-M-encoding ST131) 
play a major role in the dissemination of ESBL genes, however such a depth of 
information does not exist for isolates from animal populations (2). Human-associated 
pandemic lineages have been reported in animal populations albeit to a much lesser 
extent than in human populations (7).   
In humans, blaCTX-M variants are the globally dominant ESBL type with some variants 
exhibiting geographical associations (e.g. blaCTX-M-15 in Europe and North America and 
blaCTX-M-14 in Asia) (2). Transmission of ESBLs occurs largely  through horizontal gene 
transfer, with conjugative IncF plasmids being reported as the dominant vehicles for 
blaCTX-M genes (8,9). Previous studies using typing methodologies including WGS 




human populations (10,11). Epidemic plasmids have been reported across different 
host populations and in multiple countries (12). For example, one epidemic plasmid 
type – pCT, encoding blaCTX-M-14 – was identified in cattle and human E. coli isolates 
in England and found to exist in human isolates from several countries across 3 
continents (12).  
Antimicrobial use in food animals may provide selective pressure for resistance 
genes/plasmids which could theoretically be spread to humans (13). However, recent 
reports suggest that such transmission is limited, at least in the UK (14). In dairy 
farming, antibiotics are used both therapeutically in the treatment of common 
infections such as mastitis, and preventatively. For example, in so-called dry cow 
therapy, an antibacterial preparation inserted into a cow’s udder between lactations to 
prevent mastitis (15). A survey of dairy farms in England and Wales in 2012 revealed 
that the fourth-generation cephalosporin (4GC) cefquinome (another HP-CIA) was the 
most used dry cow therapy treatment (16). By 2017, however, only 5.3% of total dry 
cow therapy active ingredients were HP-CIAs. Indeed, there has been a significant 
decline in the use of HP-CIAs on dairy farms in the UK in recent years (17).  
Recently, we reported a survey of 53 dairy farms located in South West England where 
we investigated the prevalence of 3GC-R E. coli (18). From 1226 such isolates,  PCR 
analysis confirmed that 648/1226 (52.7%) carried blaCTX-M and 13/1226 (1.1%) carried 
a pAmpC gene. The remaining 566/1226 (46.2%) isolates did not carry any putative 
acquired 3GC-R gene, and a subsequent analysis confirmed that hyper-production of 
the chromosomally encoded AmpC β-lactamase was the mechanism of 3GC-R in 




The study reported here aimed to characterise, using WGS, representative blaCTX-M 
and pAmpC-positive E. coli isolates collected on dairy farms during our earlier 
surveillance study (18). Furthermore, our aim was to compare these isolates at strain 
and plasmid-encoded 3GC-R gene level with blaCTX-M and pAmpC positive urinary E. 
coli isolates (20) collected from humans living in the same 50 x 50 km region that was 
the location of the majority of dairy farms under study. 
 
Results and Discussion 
WGS analysis of E. coli carrying acquired 3GC-R genes from dairy farms 
One hundred and thirty-eight representative isolates, PCR-positive for blaCTX-M or 
pAmpC genes (18) and chosen to give coverage of all 42 farms positive for acquired 
3GC-R genes, were subjected to WGS (Table 1). blaCTX-M-32, encoding a group 1 
enzyme first described in a human clinical isolate in 2004 (21), was the most common 
3GC-R gene identified and was found in 79/138 sequenced isolates encompassing 27 
E. coli sequence types (STs) from 25 farms Other 3GC-R genes identified were: 
blaCTX-M-14 (18 isolates, 6 STs from 9 farms), blaCTX-M-1 (16 isolates, 8 STs from 6 
farms), blaCTX-M-15 (16 isolates, 5 STs from 10 farms), blaCMY-2 (6 isolates, 3 STs from 
3 farms), blaCTX-M-214 (3 isolates, 2 STs from 3 farms) plus one isolate harbouring 
blaDHA-1 and one isolate having both blaCTX-M-1 and blaCTX-M-14. CTX-M-214 (GenBank 
Accession No. MH121688) is a novel CTX-M-9 variant, first identified in this study, 
which differs from CTX-M-9 by a single amino acid, Ala112Thr. In all three isolates 
encoding blaCTX-M-214, the gene was identified on a contig which also encoded an IncI-





Identification and characterisation of pMOO-32 
Following observations of the high prevalence of blaCTX-M-32, a search for common 
plasmid replicon types was conducted which revealed an IncHI2-ST2 replicon in 
almost all the sequenced blaCTX-M-32-positive isolates. Conjugation experiments were 
attempted into E. coli DH5α using blaCTX-M-32-positive farm isolate DK as donor (Table 
2). Transconjugants were identified at high frequency, approximately 10-4 per donor. 
One successful transconjugant was sent for WGS employing both long and short read 
methodologies to sequence the plasmid to closure. pMOO-32 is a 226,022-bp 
conjugative plasmid belonging to the ST2-IncHI2 incompatibility group, harbouring 
repHI2 and repHI2A replication genes. It contains 245 putative ORFs and has a GC 
content of 45.5% (Figure 1). pMOO-32 encodes the following antimicrobial resistance 
genes: blaCTX-M-32, strA, strB, aph(6)-Ic, aph(3’)-IIa and tet(B) as well as genes 
encoding resistance to the heavy metal compound, tellurite (terABCDEFWXYZ) and 
a HipAB type II toxin-antitoxin system along with a second partial system (higB toxin 
gene). blaCTX-M-32 is encoded downstream of an ISECp1 element within which there is 
an ISKpn26 insertion encoded in the opposite orientation (Figure 2). This same 
genetic environment was also observed in 4 blaCTX-M-32-positive but IncHI2 plasmid-
negative ST10 isolates collected from 2 farms. There were 2 additional IncHI2 
plasmid-negative ST765 isolates, both from the same farm, that carried blaCTX-M-32 
where the immediate genetic environment differed by a truncation in ISEcp1. In these 
6 IncHI2 plasmid negative isolates, blaCTX-M-32 is carried on an IncFII plasmid not 
previously reported. 
Conjugation attempts using the pMOO-32-positive farm isolate DK as donor into a 
3GC-susceptible (3GC-S) cattle ST88 E. coli isolated from one of the study farms (18) 




successful (Table 2). ST1193 was selected as a recently described fluoroquinolone-
resistant global clone, often implicated as a cause of human infections (22), whilst 
ST88 was selected as a particularly prevalent ST among cattle isolates (23). 
Antimicrobial disc testing showed that the pMOO-32-carrying donor was, as expected 
from the genotype, resistant to ampicillin, cefotaxime, cefepime, aztreonam, 
streptomycin, neomycin, and tetracycline. The cattle ST88 and human ST1193 
transconjugants were, additional to their starting wild-type resistance profile, resistant 
to cefotaxime, cefepime and aztreonam. These results (Table 2) are indicative of the 
functionality of the blaCTX-M-32 gene harboured by pMOO-32.  
 
Epidemiology of pMOO-32-like plasmids on farms 
The complete nucleotide sequence of pMOO-32 was submitted to GenBank under 
accession number MK169211. Using this sequence as a reference, sequencing reads 
from all 73 isolates positive for blaCTX-M-32 and the IncHI2 replicon were mapped. Whilst 
there are limitations in using short read sequencing data in this way, the plasmids in 
these 73 isolates exhibited 94-100% identity to the reference sequence. Any 
differences could be attributed to a loss or gain of mobile genetic elements, but no 
major rearrangements were observed to the plasmid backbone or changes to 
resistance gene content. The isolates carrying pMOO-32-like plasmids comprised 27 
E. coli STs. On 10 farms, pMOO-32-like plasmids were found in isolates of more than 
one ST. The most frequently identified STs were ST69 and ST10, found in 18 isolates 
from 7 farms, and 6 isolates from 4 farms, respectively. Therefore, we conclude that 





We next designed a multiplex PCR, based on the pMOO-32 sequence, and used it to 
screen all group 1 blaCTX-M-PCR-positive isolates from our study farms (18) not 
previously subjected to WGS. The aim was to test them for the presence of pMOO-
32-like plasmids. It was found that 26/53 (49.1%) farms within our study area tested 
positive for the presence of a pMOO-32-like plasmid using this test. The origins and 
geographical reach of pMOO-32 remain to be established, but all positive farms were 
located in a 40 x 40 km sub-region of the wider study area, where 26/33 farms were 
positive, suggesting that the plasmid remained geographically confined at the time of 
sample collection. 
We hypothesised that the observed dominance of pMOO-32-like plasmids could be a 
consequence of the HipAB-type II toxin-antitoxin system found on the plasmid, leading 
to persistence even in the absence of antibacterial selective pressure. In support of 
this, we found that pMOO-32 was stably maintained over 10 days of passaging in the 
absence of antibiotic pressure. 100% of tested farm isolates, their respective DH5α 
transconjugants, and the human and cattle E. coli isolate transconjugants were found 
to have retained the plasmid.  
 
No evidence for recent sharing of 3GC-R E. coli and limited evidence for recent 
sharing of 3GC-R E. coli plasmids between humans and dairy farms 
The ability of pMOO-32 to readily transfer into human urinary E. coli ST1193 (Table 
2) and be maintained in the absence of antimicrobial pressure indicates the zoonotic 
potential of this plasmid. We next aimed to see if there was evidence of recent sharing 
of 3GC-R isolates or plasmids, including pMOO-32, between dairy farms and humans 




isolates WGS data (described above) with human urinary E. coli WGS data collected 
in parallel within the same 50 x 50 km geographical region (20). Since 10 dairy farms 
under study here lie outside the 50 x 50 km region (18), isolates from these farms were 
excluded.  
Core genome phylogenetic analysis was carried out using WGS data from 112 dairy 
farm and 212 human urinary E. coli isolates carrying acquired 3GC-R genes collected 
within the target region. This analysis (Figure 3) revealed only four STs including 
examples of both farm and human isolates. In no case was the single nucleotide 
polymorphism (SNP) difference between any pair of human and farm isolate core 
genomes suggestive of recent transmission. ST10 was the closest (≥205 SNPs 
different between human and cattle isolates; Figure 3 insert); the others were ST540 
(929 SNPs different), ST58 (≥1388 SNPs different) and ST69 (≥831 SNPs different). 
In contrast, there was clear evidence of recent farm-to-farm transmission of isolates 
from multiple STs (e.g. ST10 and ST69 where, in both cases, there was a 3 SNP 
minimum distance between pairs of isolates representing two farms) (Figure 3). AmpC 
hyper-producing E. coli isolates from these same farms showed a similar pattern: no 
evidence of strain sharing between dairy farms and humans but strong evidence for 
recent farm-to-farm transmission (19). We conclude therefore that 3GC-R isolates 
from farms, do not readily circulate amongst the local human population and cause 
UTI. 
We next considered transmission of plasmid-mediated 3GC-R between farm and 
human E. coli isolates (i.e. those that that have caused UTI). We found that 37/107 
blaCTX-M-positive E. coli isolates from farm samples within our 50 x 50 km study region 
carried blaCTX-M variants also seen amongst 189 blaCTX-M-positive urinary E. coli 




of the human isolates carried blaCTX-M-32 or any plasmid related to pMOO-32. By 
filtering sequenced isolates by their blaCTX-M variants and plasmid replicon types, 
plasmids that shared high degrees of sequence identity in farm and human isolates 
were identified. There were three different blaCTX-M variant/plasmid replicon type 
combinations found in both farm and human isolates. For each, the longest blaCTX-M 
containing contig was used to identify the finished NCBI sequence with the highest 
identity, which was used as a reference for read mapping-based comparisons. 
One IncI1-ST3 plasmid, found in an ST345 farm isolate, harboured blaCTX-M-1. Mapping 
of sequencing reads showed that this plasmid exhibited 100% coverage and 97.5% 
sequence identity to an unpublished ~106 kb IncI1-ST3 plasmid (pTC_N40607; 
GenBank Accession No. CP007651) found in E. coli obtained from meat/cattle isolates 
in the USA. Six human urinary E. coli isolates representing STs 23, 127, 131, 141 and 
2015 harboured blaCTX-M-1 on a plasmid that exhibited 99.4-100% coverage and 96.4-
98.7% identity when sequencing reads were mapped to pTC_N40607. 
Another plasmid type - again obtained from a single farm isolate, in this case of ST58 
- exhibited 100% coverage and 98.5% identity by read mapping to a published IncK 
plasmid, pCT (GenBank Accession No. NC_014477). pCT is ~94 kb and harbours 
blaCTX-M-14. pCT-like plasmids have been reported in both human and veterinary E. coli 
isolates across three continents (12, 23). Amongst human urinary E. coli isolates found 
in this study, two also carried pCT-like plasmids. Both isolates were the pandemic 
clone ST131, and their pCT-like plasmids exhibited 96.4 or 97.2% identity and 100% 
coverage to pCT. 
In terms of plasmids encoding pAmpC genes, we identified a blaCMY-2 encoding 




derived from an E. coli that caused urinary tract infections in dogs in Scotland (24). 
Mapping analyses showed that one out of seven blaCMY-2-carrying human urinary 
isolates (ST 80) showed 100% coverage and 99.9% identity to p96. An almost identical 
plasmid was found in one farm isolate (ST1480) that showed 99.6% coverage and 
98.9% identity to p96. As with the two blaCTX-M plasmids, this blaCMY-2 encoding plasmid 
appears to be globally widespread. Blast analysis found blaCMY-2 plasmids with >95% 
coverage and >98% identity to p96 in E. coli isolates from humans in Taiwan (25) and 
chicken meat in the USA (GenBank Accession no. CP048295). 
 
Concluding remarks 
Overall, this analysis finds no evidence of recent, direct sharing of E. coli between 
farms and the local human population that have resulted in UTI. However, three farm 
E. coli isolates carried a blaCTX-M or blaCMY-2 plasmid almost identical to one of three 
plasmids found in urinary E. coli in the local human population. However, these three 
plasmids are known to be widely disseminated in humans and animals across several 
continents. Furthermore, no human/farm plasmid pair shared 100% identity. So, whilst 
there is some general evidence of plasmids circulating between human and animal 
populations, as reported in a number of recent studies in Western countries (14,26,27), 
the overall level of overlap between UK dairy farm and human 3GC-R E. coli identified 
in this study was very small and not suggestive of any novel or recent zoonotic 
transmission events. In contrast, both recent and sustained farm-to-farm transmission 
of 3GC-R E. coli, and particularly of a newly identified epidemic plasmid pMOO-32 
across many different E. coli STs and dairy farms, was clearly seen. Identifying the 
vectors for this transmission will inform interventions that might facilitate a more rapid 






Bacterial isolates, identification, and susceptibility testing 
Details of farm sample collection and microbiological analysis has recently been 
reported (18). In brief, samples of faecally contaminated sites were collected using 
sterile overshoes on 53 dairy farms located in South West England between January 
2017 and December 2018. Samples were plated onto TBX agar (Sigma-Aldrich, 
Poole, UK) containing 16 mg.L-1 cephalexin. Up to 5 E. coli colonies per cefalexin plate 
were re-plated onto TBX agar containing 2 mg.L-1 cefotaxime to confirm resistance. 
Presence of acquired 3GC-R genes (blaCTX-M, blaSHV, blaCMY-2 and blaDHA-1) was 
confirmed by PCR. Disc susceptibility testing was performed and interpreted according 
to EUCAST guidelines (28).  
 
Conjugation 
Conjugation experiments were performed using rifampicin-resistant (Rif-R) E. coli 
DH5α with both human and cattle E. coli isolates as the recipients (Table 3). Briefly, 1 
mL each of overnight broth cultures of donor and recipient cells were mixed in a 3:1 
ratio before centrifugation and resuspension in 50 µL of PBS. Five microlitre aliquots 
were spotted onto LB agar (Oxoid, Basingstoke, UK) plates and incubated at 37°C for 
6 h. Growth was collected and resuspended in 100 µL of PBS before being plated on 
MacConkey agar (Oxoid) plates containing either 32 mg.L-1 rifampicin (for Rif-R E. coli 
DH5α) or 0.5 mg.L-1 ciprofloxacin (for strains HC4 and HG), and 2 mg.L-1 cefotaxime. 





WGS and analyses and pMOO-32 PCR 
Representative isolates were selected for WGS based on resistance phenotype, β-
lactamase gene carriage and farm of isolation, as defined previously (18). WGS was 
performed by MicrobesNG (https://microbesng.uk/) on a HiSeq 2500 instrument 
(Illumina, San Diego, CA, USA) using 2x250 bp paired end reads. Reads were 
trimmed using Trimmomatic (29) and assembled into contigs using SPAdes 3.13.0 
(30) (http://cab.spbu.ru/software/spades/). Resistance genes, plasmid replicon types 
and sequence types (according to the Achtman scheme [31]) were assigned using the 
ResFinder (32), PlasmidFinder (33), and MLST 2.0 on the Center for Genomic 
Epidemiology (http://www.genomicepidemiology.org/) platform. Enhanced genome 
sequencing (combining Illumina and MinION reads) was performed by MicrobesNG 
on one transconjugant and reads were assembled using Unicycler (34). Contigs were 
annotated using Prokka 1.2 (35).  
Reads were aligned to plasmid reference sequences using the progressive Mauve 
alignment software (36), CLC Genomics Workbench 12 (Qiagen, Manchester, UK), or 
BWA (37) and SAMtools (38), with variant positions being called  using BCFtools (39). 
pMOO-32 was visualised using the CGView server (40) 
(http://stothard.afns.ualberta.ca/cgview_server/). The most appropriate plasmid 
reference for each analysis was identified using blastn with the largest blaCTX-M 
containing contig relevant to each analysis. 
A multiplex PCR, targeting five size-distinguishable regions of pMOO-32, was 





Plasmid stability assay 
Three representative pMOO-32 PCR-positive isolates, obtained from different farms, 
and their transconjugant counterparts were subjected to 10 days of serial passaging 
on non-selective LB agar. Each day, a single colony was picked and re-streaked. After 






Sequence alignment and phylogenetic analysis was carried out using the Bioconda 
environment (41) on the Cloud Infrastructure for Microbial Bioinformatics (CLIMB) (42). 
The reference sequence was E. coli ST131 isolate EC958 complete genome 
(accession: HG941718). Sequences were first aligned to a closed reference sequence 
and analysed for SNP differences, whilst omitting insertion and deletion elements, 
using the Snippy alignment program. Alignment was then focused on regions of the 
genome found across all isolates, the core genome, using the Snippy-core program, 
thus eliminating the complicating factors of insertions and deletions 
(https://github.com/tseemann/snippy). Aligned sequences were then used to construct 
a maximum likelihood phylogenetic tree using RAxML, utilising the GTRCAT model of 
rate heterogeneity and the software’s autoMR and rapid bootstrap to find the best-
scoring maximum likelihood tree and including tree branch lengths, defined as the 
number of base substitutions per site compared (43,44). Finally, phylogenetic trees 
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138/42 79 27/25 16a 8/6 18a 6/9 16 5/10 3 2/3 1 1/1 6 3/3 
 
Table 1. Characteristics of 3GC-R 138 isolates subjected WGS. 
















S/I/R E. coli 
DH5α 
S/I/R E. coli 
DH5α TR 
S/I/R E. coli 
HG 
S/I/R E. coli 
HG TR 
S/I/R E. coli 
HC4 
S/I/R E. coli 
HC4 TR 
S/I/R 
AMP <6 R 30 S <6 R <6 R <6 R 20 S <6 R 
CTX 10 R 45 S 18 I 35 S 10 R 34 S 13 R 
CAZ 20 I 45 S 30 S 34 S 20 I 32 S 23 S 
FEP 19 R 45 S 28 S 28 S 18 R 35 S 24 I 
ETP 30 S 45 S 44 S 34 S 33 S 36 S 36 S 
ATM 15 R 45 S 24 I 34 S 15 R 35 S 19 R 
STRa <6 R 25 S 10 R <6 R <6 R 13 R <6 R 
TOB 17 S 28 S 26 S <6 R <6 R 18 S 19 S 
NEOa 8 R 20 S 12 R <6 R <6 R 14 I 8 R 
TETa <6 R 36 S <6 R <6 R <6 R 30 S <6 R 
Table 2. Disc susceptibility testing of E. coli DK and pMOO-32 transconjugants of various E. coli recipient strains.  
AMP, ampicillin; CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; ETP, ertapenem; ATM, aztreonam; STR, streptomycin; TOB, tobramycin; 
NEO, neomycin; TET, tetracycline; TR, pMOO-32 transconjugant. S, susceptible; I, intermediate, R, resistant, as defined by CLSI criteria. 
aStreptomycin and neomycin sensitivities were determined using tobramycin EUCAST interpretation guidelines, and tetracycline according to 






Isolate Source/Host ST Resistance Genes Use 
DK Cattle 155 strA, strB, aph(6)-Ic, aph(3')-IIa, tet(B), blaCTX-M-32 Donor 
HC4 Human 1193 aadA5, dfrA17, mdf(A), sul1 Recipient 
HG Cattle 88 aph(6)-Id, ant(2'')-Ia, aph(3')-Ia, aadA24, aph(3'')-Ib, 
sul1, sul2, tet(A), tet(B), blaTEM-1, blaOXA-1, catA1, floR 
Recipient 
 








Table 4. Primers used for the pMOO-32 multiplex PCR. 
 
  
Primer Sequence (5’-3’) Product Size 
(bp) 
Target 
aph(3’)-lla_F TGGCTACCCGTGATATTGCT 642 aph(3’)-lla/aph(6)-Ic junction 
aph(6)-lc_R CTGGCGGACGGGAAGTATC 
HI2A_F AGCCTTTCTCACGGTAGCAT 526 HI2 repA 
HI2A_R TTCAATTGTCGGTGAGCGTC 
TraI_F CGGGAAAAGCTGCACTCAAT 396 traI 
TraI_R AAGACTTTGTGAGCTTGGCG 
TetB_F TTCAGCGCAATTGATAGGCC 285 tetB 
TetB_R ATCCCACCACCAGCCAATAA 






Figure 1. Plasmid pMOO-32 created using CGView (40).  
The outer two rings represent predicted coding sequences (cds), facing clockwise and 
counter-clockwise, respectively. Those predicted to encode antimicrobial resistance 
proteins are shown red, plasmid replicon functions, pink, and telluride resistance 
proteins, orange. GC content is show black, above or below 50%, and GC skew is 
illustrated in the central ring in green – biased towards GC – or magenta – biased 














Figure 2. The genetic environment of blaCTX-M-32 in pMOO-32 and other IncHI2 positive, blaCTX-









Figure 3. Phylogenetic analysis of E. coli from dairy farms and human UTI collected in 
parallel in a 50 x 50 km region.  
Human isolates are noted in orange; cattle isolates are noted in blue. The reference ST131 
isolate is noted in black. Certain key STs are highlighted, particularly STs with representatives 
from human and cattle isolates: ST21 (ST540), ST69, ST58 and ST10. The insert shows a 
more detailed analysis of ST10 isolates which represents the closest relationship between a 
human and a cattle isolate: 205 SNPs different across the core genome. 
 
